The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

FAUNA BIO'S COMPARATIVE GENOMICS APPROACH FINDS NEW COMPOUNDS FOR HEART AND LUNG DISEASES

Fauna | June 15, 2022

news image

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the mo...

Read More

Industrial Impact

NEW MENARINI SILICON BIOSYSTEMS PARTNERSHIP WITH ALIVIO HEALTH EXPANDS PATIENT ACCESS TO CELLSEARCH® LIQUID BIOPSY TESTS

PRNewswire | May 22, 2023

news image

Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies, announced today its partnership with Alivio Health. This new agreement opens the door to preferred access for Alivio Health clients and providers to the valuable information offered by the CELLSEARCH CTC tests, which allow longitudinal monitoring of cancer patients at any time during the course of the disease. Starting from a simple blood draw, CELLSEARCH CTC tests provide valuable information on a ...

Read More

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

news image

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More

Medical

CELLECTIS PRESENTS CLINICAL DATA ON AMELI-01 AND PRECLINICAL DATA ON MULTIPLEX ENGINEERING FOR SUPERIOR GENERATION OF CAR T-CELLS AT ASGCT 2023

Globenewswire | May 18, 2023

news image

Cellectis a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data on its Phase 1 AMELI-01 clinical trial (evaluating UCART123) that were unveiled in an oral presentation at the 64th American Society of Hematology (ASH) annual meeting, as well as preclinical data on multiplex engineering for superior generation of CAR T-cells, at the American Society of Gene and Cell Therapy (ASGCT) 2023 A...

Read More
news image

Medical

FAUNA BIO'S COMPARATIVE GENOMICS APPROACH FINDS NEW COMPOUNDS FOR HEART AND LUNG DISEASES

Fauna | June 15, 2022

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the mo...

Read More
news image

Industrial Impact

NEW MENARINI SILICON BIOSYSTEMS PARTNERSHIP WITH ALIVIO HEALTH EXPANDS PATIENT ACCESS TO CELLSEARCH® LIQUID BIOPSY TESTS

PRNewswire | May 22, 2023

Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies, announced today its partnership with Alivio Health. This new agreement opens the door to preferred access for Alivio Health clients and providers to the valuable information offered by the CELLSEARCH CTC tests, which allow longitudinal monitoring of cancer patients at any time during the course of the disease. Starting from a simple blood draw, CELLSEARCH CTC tests provide valuable information on a ...

Read More
news image

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More
news image

Medical

CELLECTIS PRESENTS CLINICAL DATA ON AMELI-01 AND PRECLINICAL DATA ON MULTIPLEX ENGINEERING FOR SUPERIOR GENERATION OF CAR T-CELLS AT ASGCT 2023

Globenewswire | May 18, 2023

Cellectis a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data on its Phase 1 AMELI-01 clinical trial (evaluating UCART123) that were unveiled in an oral presentation at the 64th American Society of Hematology (ASH) annual meeting, as well as preclinical data on multiplex engineering for superior generation of CAR T-cells, at the American Society of Gene and Cell Therapy (ASGCT) 2023 A...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us